Biogen
05.07.2010
Sanofi-Aventis declined to comment on Friday on a Bloomberg report that it was preparing an acquisition of $20 billion or more in the U.S. as shares in the French drugmaker fell. The group, headed by Chris Viehbacher, is actively looking for acquisitions to find new sources of growth as its own product pipeline is drying out and some research projects have been pulled.
more10.03.2010
Facet Biotech has agreed to be acquired by Abbott Laboratories for $27 a share, topping a hostile offer of $17.50 a share made last year by Biogen Idec. Shares of Facet rose 67% after the announcement.
Abbott and Facet said on Tuesday that the cash deal will have a net cost of about $450 million, including a purchase price of about $722 million less Facet's cash and securities of around $272 million.
more22.01.2010
Investors welcomed the announcement that Biogen Chief Executive James Mullen will be leaving the company, with some saying he had lost credibility as a leader. The move came less than a month after the biotechnology company said its chairman would step down and just seven months after activist investor Carl Icahn succeeded in placing two members onto Biogen's board.
more